Cargando…

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

PURPOSE: Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), real-world data about the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seok-Jin, Hyeon, Jiyeon, Cho, Inju, Ko, Young Hyeh, Kim, Won Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473267/ https://www.ncbi.nlm.nih.gov/pubmed/30025443 http://dx.doi.org/10.4143/crt.2018.191

Ejemplares similares

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
por: Yang, Qing-Ming, et al.
Publicado: (2014)

Epstein-Barr virus and the origin of Hodgkin lymphoma
por: Vockerodt, Martina, et al.
Publicado: (2014)

Epstein Barr Virus-Associated Hodgkin Lymphoma
por: Carbone, Antonino, et al.
Publicado: (2018)

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
por: Kim, Seok Jin, et al.
Publicado: (2020)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
por: Kim, Miso, et al.
Publicado: (2021)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma
por: Yu, Tsung-Ying, et al.
Publicado: (2020)

Molecular Characterisation of Epstein–Barr Virus in Classical Hodgkin Lymphoma
por: Begić, Valerija, et al.
Publicado: (2022)

Evaluation of plasma Epstein–Barr virus DNA as a biomarker for Epstein–Barr virus–associated Hodgkin lymphoma
por: Usha, Masuma Khatun, et al.
Publicado: (2021)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing
por: Cho, Junhun, et al.
Publicado: (2021)

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
por: Massaro, Fulvio, et al.
Publicado: (2022)

The Spectrum of Epstein-Barr Virus-Associated Lymphoproliferative Disease in Korea: Incidence of Disease Entities by Age Groups
por: Cho, Eun-Yoon, et al.
Publicado: (2008)

Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma
por: Maeng, Chi Hoon, et al.
Publicado: (2017)

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
por: Cho, Inju, et al.
Publicado: (2020)

Chronic Epstein Barr virus infection leading to classical Hodgkin lymphoma
por: Sarwari, Nawid M., et al.
Publicado: (2016)

Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma
por: Nagel, Stefan, et al.
Publicado: (2022)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Contribution of Epstein–Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma
por: Vrzalikova, Katerina, et al.
Publicado: (2018)

Hemophagocytic Lymphohistiocytosis in a Patient with Hodgkin Lymphoma, HIV, and Epstein-Barr Virus
por: Javed, Faiza, et al.
Publicado: (2023)

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
por: Younes, Anas, et al.
Publicado: (2017)

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2019)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma
por: Lim, Jing Quan, et al.
Publicado: (2020)

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
por: Armand, Philippe, et al.
Publicado: (2019)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
por: Park, Ha Young, et al.
Publicado: (2016)

Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma
por: Le‐Nguyen, Alexandre, et al.
Publicado: (2021)

Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review
por: Hossain, Md Fahad, et al.
Publicado: (2023)

Epidemiology of Classical Hodgkin Lymphoma and Its Association with Epstein Barr Virus in Northern China
por: Huang, Xin, et al.
Publicado: (2011)

The Role of Epstein-Barr Virus LMP-1 Immunohistochemical Staining in Childhood Hodgkin Lymphoma
por: Tanyildiz, Hikmet Gulsah, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bkj7n6vbquvpalbosu67rpjni8